Positron Emission Tomography (PET) and breast cancer in clinical practice

European Journal of Radiology

Volumn 69, Issue 1, 2009, Pages 50-58

  Lavayssière, Robert ^a,b   Cabée, Anne Elizabeth ^a,b,c   Filmont, Jean Emmanuel ^b,d  

^a Centre d'Imagerie Paris Nord   (France)

^b Institut du Sein Henri Hartmann (ISHH)   (France)

^c Centre RMX   (France)

^d AMERICAN HOSPITAL OF PARIS   (France)

Author keywords

Breast cancer; Drug development; MRI; Position Emission Tomography (PET); Prognosis; Residual disease; Response assessment

Indexed keywords

BREAST CANCER; DRUG DEVELOPMENT; MRI; POSITION EMISSION TOMOGRAPHY (PET); PROGNOSIS; RESIDUAL DISEASE; RESPONSE ASSESSMENT;

COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC RADIOGRAPHY; ELECTRIC INSTRUMENT TRANSFORMERS; ELECTRONS; IONIZING RADIATION; MEDICAL IMAGING; POSITRON ANNIHILATION SPECTROSCOPY; POSITRONS; RADIATION; RADIOLOGY; TOMOGRAPHY;

POSITRON EMISSION TOMOGRAPHY;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

BREAST NEOPLASMS; HUMANS; IMAGE ENHANCEMENT; MASS SCREENING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 58149482067     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.07.039     Document Type: Article

References (25)

1. Juweid M.E., and Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354 (2006) 496-507
2. Koh D.M., Cook G.J.R., and Husband J.E. New horizons in oncologic imaging. N Engl J Med 348 (2003) 25
3. Tafra L. Positron emission tomography (PET) and mammography (PEM) for breast cancer: importance to surgeons. Ann Surg Oncol 14 1 (2006) 3-13
4. Rohren E.M., Turkington T.G., and Coleman R.E. Clinical applications of PET in oncology. Radiology 231 (2004) 305-332
5. Blodgett T.M., Meltzer C.M., and Townsend D.W. PET/CT: form and function. Radiology 242 (2007) 360-385
6. von Schulthess G.K., Steinert H.C., and Hany T.F. Integrated PET/CT: current applications and futures directions. Radiology 238 2 (2006) 405-422
7. Kelloff G.J., Hoffman J.M., Johnson B., et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 1 April (8) (2005)
8. Rosen E.L., Eubank W.B., and Mankoff D.A. FDG PET, PET/CT and breast cancer imaging. Radiographics 27 (2007) S215-S229
9. Lim H.S., Yoon W.Y., Chung T.W., et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 27 (2007) S197-S213
10. Veronesi U., De Cicco C., and Galimberti V.E. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18 3 (2007) 473-478
11. Rieber A., Schirrmeister H., Gabelmann A., et al. Pre-operative staging of invasive cancer with MR mammography and/or PET: boon or bunk?. Br J Radiol 75 (2002) 789-798
12. Eubanks W.B., Markoff D., Bhattacharya M., et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR 183 (2004) 479-486
13. Stadnik T.W., Everaert H., Makkat S., Sacré R., Jan Lamote J., and Bourgain C. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging-initial findings. Eur Radiol 16 10 (2006) 2153-2160
14. Brix G., Henze M., Knopp M.V., et al. Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Eur Radiol 11 (2001) 2058-2070
15. Rousseau C., Devillers A., Sagan C., et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24 34 (2006) 5366-5372
16. Goerres G.W., Michel S.C., Fehr M.K., et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 13 7 (2003) 1635-1644
17. Grahek D., Montravers F., Kerrou K., Aide N., Lotz J.P., and Talbot J.N. [18F] FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 31 (2004) 179-188
18. Yap C.S., Seltzer M.A., Schiepers C., et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 42 (2001) 1334-1337
19. Liu C.S., Shen Y.Y., Lin C.C., Yen R.F., and Kao C.H. Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 32 (2002) 244-247
20. Uematsu T., Yuen S., Yukisawa S., et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR 184 (2005) 1266-1273
21. Nakamoto Y., Cohade C., Tatsumi M., Hammoud D., and Walh R. CT appearance of bone metastases detected with FDG PET as part of the same examination. Radiology 237 2 (2005) 627-634
22. Yang S.N., Liang J.A., Lin F.J., Kao C.H., Lin C.C., and Lee C.C. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J. Cancer Res Clin Oncol 128 June (6) (2002) 325-328
23. Schaefer J.-F., and Schlemmer H-PW. Total-body MR-imaging in oncology. Eur Radiol 16 (2006) 2000-2015
24. Schmidt G.P., Haug A.R., Schoenber S.O., and Reiser M.F. Whole-body MRI and PET-CT in the management of cancer patients. Eur Radiol 16 (2006) 1216-1225
25. Semple S.I., Gilbert F.J., Staff R.T., et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol 14 (2004) 2038-2045